Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study
about
sameAs
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisEffect of particulate matter air pollution on C-reactive protein: a review of epidemiologic studiesCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseAnithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapyCardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxibMeasuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?Time variability of C-reactive protein: implications for clinical risk stratification.Strength Training for Arthritis Trial (START): design and rationale.Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responsesC-reactive protein and risk of colorectal adenoma according to celecoxib treatment.Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stentsAssociation between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort.Inflammatory markers and mortality among US adults with obstructive lung function.Selective COX-2 inhibitors and risk of myocardial infarction.Circulating levels of inflammatory markers and mammographic density among postmenopausal women.Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.Celecoxib and cardiovascular risks.Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?Blood pressure and endothelial function in healthy, pregnant women after acute and daily consumption of flavanol-rich chocolate: a pilot, randomized controlled trial.Cyclooxygenase products and atherosclerosisThe Quebec Heart Institute: 50 years of excellence in cardiologyCOX-1 and vascular disease.The effect of salsalate therapy on endothelial function in a broad range of subjects.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products.The cardiovascular safety of celecoxib.Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
P2860
Q21195404-1512596B-89A2-4535-A9F7-D6C5E94FB807Q27000990-FB529AFC-67DB-49A3-913B-6773176DC4FAQ28219483-2477F05E-5DAC-4FF6-8EE9-4048D325D458Q28220433-A6C5F86D-DFF9-42D1-9F26-3CC408B35D4BQ28222097-92282BC3-1194-4175-AC1D-D5BD8F2A0285Q33528966-D3816663-D13F-461C-B1DD-29F649D1E76FQ34665888-9EB02190-33DF-44EF-985C-215D20C78670Q34820446-3F7A1930-7657-4A42-9105-3D31A7EFEAE9Q35005089-B2667D5D-E90C-4209-B721-ABDA630D38BDQ35077490-57ECFA77-77D9-48EF-A17E-8A27478A80C2Q35152176-CB7F56DE-ABF0-461D-B6C7-4C36B0018D60Q35648213-DBEAD57D-6842-4D27-ABA6-00748CCC38C1Q35733402-9F7ACE31-26DA-44A6-BAB8-A97A12760707Q36036012-0CBF1AD9-3EB8-41CA-B0D1-F09988F7D5B1Q36173750-FA8B1C1D-703F-4C20-991B-4FEA29581A0BQ36201439-41C215A2-E190-4A5B-A7B1-9A3915585995Q36233306-3800AFC2-A1AC-46B6-B3B2-36F27D490688Q36299969-2465AD15-E698-4D28-8539-259F775C3238Q36645806-3F7620B4-27F0-43C3-BA8D-3536AE0C7D84Q36794015-80BE215B-EBE8-49E4-9F28-E2FA26182C0EQ37071164-23282A99-CD01-4B4E-BF8A-1940EA599AE8Q37478476-69372F5F-2C94-44BC-8ACC-EE3A0774F6CCQ37530433-E7E17760-E4E4-4933-A45E-46B7FA3911B1Q37648486-B0DC40B7-C97B-4D3B-967D-3731086A47E4Q38008700-0E9FB024-4D3D-4BD8-824F-3C2D42345298Q38170115-368BBFC3-4A84-468D-9A9F-FB67A456BA3EQ40377176-19138677-281A-412B-9D04-841B4D5E1A2EQ43234063-CBFEBB7D-697E-4ED3-8C08-3776794C975AQ46743815-D0907EAB-61A7-40B3-81C3-2375E0FD8A8F
P2860
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@ast
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@en
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@nl
type
label
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@ast
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@en
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@nl
prefLabel
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@ast
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@en
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@nl
P2093
P921
P1433
P1476
Impact of prolonged cyclooxyge ...... mized placebo-controlled study
@en
P2093
Fernand Bertrand
Gilles R Dagenais
Luce Boyer
Martin Noel
Peter Bogaty
Serge Simard
P356
10.1161/01.CIR.0000139338.12464.5F
P407
P577
2004-08-24T00:00:00Z